{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:42:09Z","timestamp":1788316929317,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with large B-cell lymphoma (LBCL) progressing after CAR-T therapy experience poor survival and lack standardized treatment strategies. Prognostic tools are needed to guide decision-making at relapse. The Post-CAR Prognostic Index (PC-PI), recently proposed by Iacoboni et al., combines five routine clinical variables to stratify outcomes after CAR-T failure: ECOG (&gt;\u20090), hemoglobin (&lt;\u200910\u00a0g\/dL), LDH (\u2265\u20092xULN), number of extranodal sites (&gt;\u20091) and time from CAR-T to progression (&lt;\u20094 months). We evaluated the PC-PI in a retrospective multicenter study including 125 LBCL patients relapsing or refractory after axicabtagene-ciloleucel or tisagenlecleucel, treated between 2019 and 2023 across 16 Italian centers belonging to the Fondazione Italiana Linfomi network. Median overall survival (OS) was 4.9 months, with 6- and 12-month OS rates of 44.9% and 28.5%, respectively. The PC-PI discriminated prognosis effectively: high-risk patients had a median OS of 1.8 months, intermediate-high 2.2, intermediate-low 8.7, while in the low-risk group median OS was not reached (p&lt;0.0001). Results remained consistent after excluding patients receiving only palliative care. Post-progression therapy markedly influenced survival: patients receiving active treatment achieved a median OS of 7.3 months versus 0.7 without further therapy (p&lt;0.0001). Bispecific antibodies conferred the best outcomes (HR 0.44, p=0.02), with 6- and 12-month OS rates of 90% and 55%. Our findings confirm the prognostic value of the PC-PI and support its use in clinical practice as a tool for risk-adapted management of LBCL after CAR-T failure.<\/jats:p>","DOI":"10.1186\/s13045-025-01771-6","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:44:34Z","timestamp":1767887074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure"],"prefix":"10.1186","volume":"19","author":[{"given":"Mirko","family":"Farina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Maiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Schiattone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Lisa","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tomarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Scapinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Marangon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pelliccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sciarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1771_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1771_CR2","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol [Internet]. 2021 [cited 2022 Mar 22];22:1403\u201315. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34516954\/","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"1771_CR3","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet [Internet]. 2020 [cited 2025 Sep 13];396:839\u201352. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673620313660","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"1771_CR4","doi-asserted-by":"crossref","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood [Internet]. 2022 [cited 2025 Sep 13];140:2584\u201393. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36122385\/","DOI":"10.1182\/blood.2022016945"},{"key":"1771_CR5","doi-asserted-by":"crossref","unstructured":"Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia [Internet]. 2023 [cited 2025 Sep 13];37:154\u201363. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36335261\/","DOI":"10.1038\/s41375-022-01739-2"},{"key":"1771_CR6","doi-asserted-by":"crossref","unstructured":"Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol [Internet]. 2019 [cited 2025 Sep 13];94:E209. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6776079\/","DOI":"10.1002\/ajh.25505"},{"key":"1771_CR7","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, et al. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025;9:3955\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2024015719.","journal-title":"Blood Adv"},{"key":"1771_CR8","doi-asserted-by":"publisher","unstructured":"Iacoboni G, Iraola-Truchuelo J, O\u2019Reilly M, Navarro V, Menne T, Kwon M, et al. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. HemaSphere. 2024;8. https:\/\/doi.org\/10.1002\/hem3.62","DOI":"10.1002\/hem3.62"},{"key":"1771_CR9","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","volume":"7","author":"J Zurko","year":"2023","unstructured":"Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, et al. Peri\u2013CAR-T practice patterns and survival predictors for all CAR-T patients and post\u2013CAR-T failure in aggressive B-NHL. Blood Adv. 2023;7:2657\u201369.","journal-title":"Blood Adv"},{"key":"1771_CR10","doi-asserted-by":"crossref","unstructured":"Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F et al. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment. J Hematol Oncol [Internet]. 2024 [cited 2025 Sep 13];17. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39468591\/","DOI":"10.1186\/s13045-024-01608-8"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01771-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T18:02:42Z","timestamp":1768154562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01771-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01771-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"EL: Roche (honoraria), Amgen (honoraria); MF: BMS, Gilead (travel grant), Jazz (travel grant), Novartis (horaria, travel grant; MM: BeOne (speaker\u2019s honoraria) MN: Abbvie, BMS (Speaker\u2019s Honoraria); Abbvie, BMS, Istituto Gentili (Advisory Board); Abbvie, Johnson & Johnson, Novartis (Support for attending meetings and\/or travel); FZ: Janssen Cilag, Abbvie, Gilead, Lilly, Amgen, Grifols, Sanofi, Takeda, Novartis, BeOne, Incyte, Astrazeneca;","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}